Edgar Filing: Atara Biotherapeutics, Inc. - Form 4

	rapeutics, Inc.										
Form 4	2016										
February 11,									OMB A	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru	Check this box if no longer subject to Section 16. Form 4 or								January 3 Expires: 200 Estimated average burden hours per response 0.		
1(b). (Print or Type F	Responses)										
1. Name and Address of Reporting Person <u>*</u> Soffer Gad			2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]					5. Relationship of Reporting Person(s) to Issuer			
(Last) 701 GATEV BOULEVA	3. Date of Earliest Transaction (Month/Day/Year) 02/09/2016					Director XOfficer (give below)	X_Officer (give title Other (specify				
				ndment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
SOUTH SA FRANCISC	N O, CA 94080							Form filed by M Person	Iore than One Re	eporting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	Derivative S	ecurit	ies Acc	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Yea	r) Executio any		3. Transacti Code (Instr. 8)	4. Securit on(A) or Dis (D) (Instr. 3, 4	ies Ac sposed 4 and 5 (A) or	quired of	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common	02/00/2016			•	48,447	٨	¢ ()	120 460	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

А

02/09/2016

Stock

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

D

120,460

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

(1)

А

\$0

1. Title of Derivative Security (Instr. 3)	or Exercise		3A. Deemed Execution Dat any (Month/Day/Y	on Date, if Transaction Code c Day/Year) (Instr. 8) I S (I I C ((5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year) ivative urities uired or posed D) tr. 3,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Repo	rting O	wners										
Repor	orting Owner	Name / Address		Relationships								
			Director	10%	Owner (Officer		Othe	er			

Chief Operating Officer

Edgar Filing: Atara Biotherapeutics, Inc. - Form 4

Soffer Gad 701 GATEWAY BOULEVARD SUITE 200 SOUTH SAN FRANCISCO, CA 94080

Signatures

/s/ Tina Gullotta, Attorney-in-Fact for Gad Soffer

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service.

02/11/2016

Date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.